Recombinant Human CD19 Protein

<strong>Recombinant Human CD19 Protein</strong>_x000D_ <strong>Catalog number:</strong> B2019269_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 µg_x000D_ <strong>Molecular Weight or Concentration:</strong> 31.6 kDa_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20°C_x000D_ <strong>Keywords:</strong> B4 Protein, Human; CVID3 Protein, Human_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Zhao Z, Condomines M, van der Stegen SJC, Perna F, Kloss CC, Gunset G, Plotkin J, Sadelain M. Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells Cancer Cell. 2015 Oct 12;28(4):415-428._x000D_ 2: Sommermeyer D, Hill T, Shamah SM, Salter AI, Chen Y, Mohler KM, Riddell SR. Fully human CD19-specific chimeric antigen receptors for T-cell therapy Leukemia. 2017 Oct;31(10):2191-2199._x000D_ 3: Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, Maric I, Raffeld M, Nathan DA, Lanier BJ, Morgan RA, Rosenberg SA. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood. 2010 Nov 18;116(20):4099-102._x000D_ 4: Gisler R, Akerblad P, Sigvardsson M. A human early B-cell factor-like protein participates in the regulation of the human CD19 promoter Mol Immunol. 1999 Oct-Nov;36(15-16):1067-77._x000D_ 5: Kido H, Okumura Y. MSPL/TMPRSS13 Front Biosci. 2008 Jan 1;13:754-8._x000D_ 6: Uckun FM, Myers DE, Qazi S, Ozer Z, Rose R, D'Cruz OJ, Ma H. Recombinant human CD19L-sTRAIL effectively targets B cell precursor acute lymphoblastic leukemia J Clin Invest. 2015 Mar 2;125(3):1006-18._x000D_ 7: García-Sanz R, Jiménez C, Puig N, Paiva B, Gutiérrez NC, Rodríguez-Otero P, Almeida J, San Miguel J, Orfão A, González M, Pérez-Andrés M. Origin of Waldenstrom's macroglobulinaemia Best Pract Res Clin Haematol. 2016 Jun;29(2):136-147._x000D_ 8: Sadelain M. CAR therapy: the CD19 paradigm J Clin Invest. 2015 Sep;125(9):3392-400._x000D_ 9: Pillai V, Maude SL. CART attack Blood. 2017 Jul 13;130(2):229._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/32205861">10: Fousek K, Watanabe J, Joseph SK, George A, An X, Byrd TT, Morris JS, Luong A, Martínez-Paniagua MA, Sanber K, Navai SA, Gad AZ, Salsman VS, Mathew PR, Kim HN, Wagner DL, Brunetti L, Jang A, Baker ML, Varadarajan N, Hegde M, Kim YM, Heisterkamp N, Abdel-Azim H, Ahmed N. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression Leukemia. 2021 Jan;35(1):75-89. </a>_x000D_ _x000D_ <strong>Products Related to Recombinant Human CD19 Protein can be found at</strong> <a href="https://moleculardepot.com/product-category/Proteins/"> Proteins</a>